NEUMORA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.19 USD | -5.94% |
|
-0.65% | -46.10% |
| May. 07 | Neumora Therapeutics Shares Fall as Q1 Loss Narrows | MT |
| May. 07 | Neumora Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 2,604 | 1,466 | - | - |
| Enterprise Value (EV) 1 | 2,140 | 988.1 | 772.9 | 1,466 |
| P/E ratio | -4.7 x | -5.74 x | -5.92 x | -5.05 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | 35.7 x |
| EV / Revenue | - | - | - | 35.7 x |
| EV / EBITDA | -8.51 x | -4.1 x | -2.9 x | -4.65 x |
| EV / FCF | -13.1 x | -4.46 x | -3.07 x | -4.99 x |
| FCF Yield | -7.64% | -22.4% | -32.5% | -20% |
| Price to Book | 5.77 x | 5.3 x | 2.82 x | 2.27 x |
| Nbr of stocks (in thousands) | 152,703 | 159,524 | - | - |
| Reference price 2 | 17.05 | 9.190 | 9.190 | 9.190 |
| Announcement Date | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 41.02 |
| EBITDA 1 | - | -251.4 | -241 | -266.8 | -315.3 |
| EBIT 1 | - | -252.1 | -263.6 | -279.3 | -367.1 |
| Operating Margin | - | - | - | - | -894.97% |
| Earnings before Tax (EBT) 1 | - | -235.7 | -257.2 | -284.7 | -418.9 |
| Net income 1 | -130.9 | -235.9 | -257.2 | -267.2 | -358.9 |
| Net margin | - | - | - | - | -874.93% |
| EPS 2 | -0.6100 | -3.630 | -1.600 | -1.552 | -1.818 |
| Free Cash Flow 1 | - | -163.4 | -221.5 | -251.5 | -293.5 |
| FCF margin | - | - | - | - | -715.57% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - |
| Announcement Date | 5/2/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA 1 | -56.69 | -113.8 | - | -59 | -61 | -62 | - | - |
| EBIT 1 | -56.86 | -114 | -60.07 | -64.1 | -68.45 | -70.9 | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -53.03 | -108.5 | -53.72 | -64.1 | -68.45 | -70.9 | - | - |
| Net income 1 | -53.03 | -108.7 | -53.72 | -64.1 | -68.45 | -70.9 | - | - |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | - | -0.7100 | -0.3400 | -0.4050 | -0.4300 | -0.4250 | -0.3600 | -0.3700 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 11/1/23 | 3/7/24 | 5/7/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | 464 | 478 | 693 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -163 | -222 | -252 | -294 |
| ROE (net income / shareholders' equity) | - | -51.2% | -58.1% | -58.1% | -43.9% |
| ROA (Net income/ Total Assets) | - | -51.2% | -54% | -52.7% | -41% |
| Assets 1 | - | 461.2 | 475.9 | 507 | 876.3 |
| Book Value Per Share 2 | - | 2.950 | 1.740 | 3.260 | 4.050 |
| Cash Flow per Share 2 | - | -2.510 | -0.8900 | -0.9500 | - |
| Capex 1 | - | 0.12 | 8 | 0.84 | 1 |
| Capex / Sales | - | - | - | - | 2.44% |
| Announcement Date | 5/2/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
9.19
USD
Average target price
24.71
USD
Spread / Average Target
+168.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -46.10% | 1.47B | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- NMRA Stock
- Financials Neumora Therapeutics, Inc.